Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

2.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harnessing nanotechnology: Transforming ocular drug delivery with advanced hydrogel systems.

Bioengineering & translational medicine·2026
Same author

TACE-induced liver injury in hepatocellular carcinoma: mechanisms, prediction, and prevention in the era of gut microbiota and inflammasome research.

Clinics and research in hepatology and gastroenterology·2026
Same author

Metal-center electron affinity modulates multicolor electrochromism in 2D conjugated metal-organic frameworks.

Nature communications·2026
Same author

Bimetallic-Node-Occupied MOF With Glycoside Hydrolase Activity for Efficient Bacterial Biofilm Hydrolysis.

Angewandte Chemie (International ed. in English)·2026
Same author

Overlapping expression characteristics of ubiquitination-related genes in periodontitis and renal cell carcinoma: transcriptomic analysis and experimental validation.

BMC oral health·2026
Same author

Evaluating data extraction error by a large language model from randomised controlled trials: a large-scale empirical study.

BMJ evidence-based medicine·2026

Related Experiment Video

Updated: May 7, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.6K

Tenecteplase: biochemical and clot lysis activity comparisons.

Jan Bechmann1, Ira Schmid1, Simone Brand1

  • 1Boehringer Ingelheim Pharma GmbH and Co., KG, Biberach an der Riss, Germany.

Frontiers in Pharmacology
|January 6, 2025
PubMed
Summary

This study found significant fibrinolytic and biochemical differences between tenecteplase products Metalyse® and Mingfule®. These variations question the generalizability of clinical data across different tenecteplase formulations.

Keywords:
clot lysiscopyfibrinolysisglycosylationtenecteplasethrombosis

More Related Videos

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

787
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.6K

Related Experiment Videos

Last Updated: May 7, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.6K
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

787
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.6K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Biotechnology

Background:

  • Alteplase has been the standard fibrinolytic treatment for acute cardiovascular and cerebrovascular events.
  • Tenecteplase, an optimized alteplase variant, offers improved pharmacokinetic and pharmacodynamic properties.
  • Multiple tenecteplase products are available, necessitating comparative quality assessments.

Purpose of the Study:

  • To compare the fibrinolytic activity and product quality of Metalyse® (originator tenecteplase) and Mingfule® (tenecteplase copy).
  • To identify biochemical and functional differences between the two tenecteplase formulations.

Main Methods:

  • Systematic analysis of biochemical and fibrinolytic properties using routine quality testing assays.
  • Mass spectrometry and surface plasmon resonance assays to evaluate molecular characteristics.
  • Host cell protein quantification and clot lysis testing after plasmin incubation.

Main Results:

  • Mingfule® exhibited lower clot lysis activity and reduced two-chain tenecteplase content compared to Metalyse®.
  • Significant differences were observed in glycosylation patterns (sialic acid, galactosylation, fucosylation) and charge heterogeneity.
  • Mingfule® showed distinct binding affinities to clearance receptors and contained substantial host cell proteins, unlike Metalyse®.

Conclusions:

  • Meaningful fibrinolytic and biochemical disparities exist between Mingfule® and Metalyse® tenecteplase.
  • These differences raise concerns regarding the extrapolation of clinical study data across various tenecteplase products.
  • Further research is needed to ensure therapeutic equivalence and patient safety with different tenecteplase formulations.